Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of October 2022

 

 

Commission File Number:  001-39034

 

 

BELLUS HEALTH INC.

---

 (Name of registrant)

---

275 Armand-Frappier Blvd.

 

Laval, Québec

 

H7V 4A7

 

Canada

---

(Address of principal executive offices)

---

  

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

☐   Form 20-F

☒ Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):   ☐

  

---

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	BELLUS Health Inc.
Date: October 10, 2022	By:	/s/ Ramzi Benamar
		Name:    Ramzi Benamar
		Title:      Chief Financial Officer

 

---

 

Form 6-K Exhibit Index

 

Exhibit Number		Document Description
99.1		News Release dated October 10, 2022. BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting.